• In late July 2026, Merit Medical Systems reported second-quarter 2026 results showing sales of US$418.84 million and net income of US$38.8 million, with both basic and diluted EPS from continuing operations at US$0.65, and also delivered higher sales and earnings for the first half of 2026 versus a year earlier.
• Alongside these results, the company raised its full-year 2026 revenue outlook to US$1.631 billion–US$1.643 billion, underscoring how stronger-than-expected first-half performance, recent acquisitions, and efficiency gains are reshaping its near-term growth and profitability profile.
• We’ll now examine how Merit’s raised 2026 revenue guidance and improved margins influence the previously outlined investment narrative for the company.

Uncover the next big thing with 21 elite penny stocks that balance risk and reward.

Merit Medical Systems Investment Narrative Recap

To own Merit Medical Systems, you need to believe it can keep shifting toward higher margin therapeutic platforms while managing reimbursement, tariff and China headwinds. The latest Q2 beat and raised 2026 revenue outlook support the near term catalyst of margin improvement, but they do not fully resolve key risks around WRAPSODY reimbursement delays and ongoing tariff pressure, which still have the potential to weigh on earnings if conditions worsen.

The most relevant recent announcement here is the July 30 guidance raise to US$1.631 billion to US$1.643 billion in 2026 revenue, alongside higher non GAAP EPS guidance. This update ties directly into the thesis that efficiency gains, acquisitions like BioLife and View Point Medical, and better execution can lift profitability, even as investors weigh product recall activity and reimbursement uncertainty as important counterpoints to the growth story.

Yet behind the upgraded 2026 guidance, investors should be aware of how unresolved WRAPSODY reimbursement delays and tariff costs could still...

Merit Medical Systems' narrative projects $1.8 billion revenue and $213.7 million earnings by 2029.

Uncover how Merit Medical Systems' forecasts yield a $89.55 fair value, a 5% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were already modeling about US$1.9 billion of revenue and US$223 million of earnings by 2029, so this stronger quarter may either reinforce that more aggressive oncology and endoscopy growth view or prompt a rethink if acquisition driven momentum and margin gains start to look less certain in light of the very same integration and uptake risks you now see emerging in the latest results.

Explore 2 other fair value estimates on Merit Medical Systems - why the stock might be worth as much as 38% more than the current price!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Merit Medical Systems research is our analysis highlighting 3 key rewards that could impact your investment decision.
• Our free Merit Medical Systems research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Merit Medical Systems' overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• AI is about to change healthcare. These 41 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 29 best rare earth metal stocks of the very few that mine this essential strategic resource.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 16 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.